Schrodinger Inc. logo

SDGR

NASDAQ

Schrodinger Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2020
Website
News25/Ratings12

Schrödinger, Inc. provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates through two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. has strategic collaborations with Thermo Fisher Scientific to extend the use of cryo-EM in connection within silico compound screening to accelerate drug discovery; Bristol Myers Squibb Company to discover, develop, and commercialize therapeutics in multiple disease areas; NVIDIA designed to harness DGX SuperPODs; Zai Lab Limited to discover, develop, and commercialize a program in oncology targeting DNA damage response; and The University of Texas MD Anderson Cancer center to develop WEE1 program. The company was incorporated in 1990 and is headquartered in New York, New York.

News · 26 weeks40-71%
2025-10-26: 22025-11-02: 42025-11-09: 02025-11-16: 02025-11-23: 02025-11-30: 02025-12-07: 12025-12-14: 22025-12-21: 02025-12-28: 02026-01-04: 12026-01-11: 12026-01-18: 02026-01-25: 12026-02-01: 02026-02-08: 52026-02-15: 12026-02-22: 42026-03-01: 102026-03-08: 12026-03-15: 22026-03-22: 12026-03-29: 02026-04-05: 02026-04-12: 32026-04-19: 1
2025-10-262026-04-19
Mix2990d
  • Insider16(55%)
  • Other6(21%)
  • SEC Filings4(14%)
  • Earnings3(10%)

Latest news

25 items